Tag Archives: pfe

Pfizer Buying Hospira To Inject Growth Into Generics

Big pharma Pfizer (PFE) agreed to buy specialty generics firm Hospira Thursday in a $17 billion deal, sending Hospira’s stock up 35% to a record high. Pfizer agreed to pay $90 a share in cash for Hospira (HSP), which sells generic injectables along with devices and systems to administer them. The firm said it should add 10 to 12 cents to EPS in the first year after the deal closes, which Pfizer expects to occur in the second half of this year.

Pfizer Licenses Opko’s Long-Acting Growth Hormone

Biotech Opko Health found a big-pharma partner for its human-growth drug candidate in the form of Pfizer on Monday in a deal that could be worth as much as $570 million. Opko Health (OPK) stock was near 9, up 9% in morning trading — a more than three-month high — on the stock market today. The deal between Opko and Pfizer (PFE) concerns hGH-CTP, a long-acting form of human growth hormone (hGH) intended to treat adults and children with stunted

Shire Can Thrive Without AbbVie, Say Analysts

Specialty drugmaker Shire faced a future as a stand-alone company Thursday after AbbVie directors late Wednesday voted against a planned acquisition. Investors and analysts seemed optimistic, though, as Shire (SHPG) stock was up 3% in early trading on the stock market today, near 175.50. Leerink analyst Jason Gerberry wrote in a research note Thursday that Shire is unlikely to attract another buyer at this point. Though Pfizer (PFE) and Allergan